By Connor Hart
Shares of MoonLake Immunotherapeutics rose after the company said a late-stage trial of its treatment for moderate-to-severe hidradenitis suppurativa showed consistent and further improvement in all clinical scores at 52 weeks, compared with an earlier readout at 16 weeks.
The stock climbed 22%, to $23.56, in premarket trading Monday. Through Friday's close, shares are up more than 60% since the beginning of the year, despite having fallen roughly 57% over the past 52 weeks.
The biotechnology company said before the bell that the data supports the treatment's, sonelokimab, potential best-in-class and best-in-disease profile, with responses that are higher than those observed in trials of competing treatments.
Chief Executive Jorge Santos da Silva said sonelokimab showed strength across most, if not all, metrics that matter in hidradenitis suppurativa. These include strong early efficacy, sustained and leading improvement over time, a consistent safety profile and convenience in dosing, it said.
Moving forward, MoonLake said it plans to submit a biologics license application to the U.S. Food and Drug Administration for sonelokimab at the end of September, targeting to launch the treatment next year.
Hidradenitis suppurativa is a severely debilitating chronic skin condition resulting in irreversible tissue destruction which manifests as painful inflammatory skin lesions.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
June 22, 2026 07:14 ET (11:14 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.